Jacobs Levy Equity Management
OREX

Jacobs Levy Equity Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Jacobs Levy Equity Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-133,658
Closed -$172K – 1130
2017
Q4 		$172K Buy
133,658
+42,119
+46% +$68.6K ﹤0.01% 925
2017
Q3 		$194K Buy
+91,539
New +$223K ﹤0.01% 870
2017
Q2 		– Sell
-24,100
Closed -$83K – 1099
2017
Q1 		$83K Buy
+24,100
New +$95.1K ﹤0.01% 870

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jacobs Levy Equity Management's OREX Position: Q1 2018 in Review

Jacobs Levy Equity Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 133,658 shares — an estimated $172K sold.

Jacobs Levy Equity Management first reported a position in OREX in Q1 2017 and held it in 3 quarters. The position peaked at $194K in Q3 2017. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

  • Jacobs Levy Equity Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 133,658 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $172K.
  • Jacobs Levy Equity Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2017 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Orexigen Therapeutics, Inc. position peaked at $194K in Q3 2017.
  • 27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2018, filed 15 May 2018.